Trial-Results center  
Clinical trial results database Feedback    Home

Systematic review and meta-analysis

This trial is included in the following systematic reviews and meta-analyses:

pulmonary hypertension - All mecanism - all patients


Related trials

PACES (Simonneau), 2008 - Sildenafil vs Placebo

EARLY (Galie), 2008 - Bosentan vs Placebo

ARIES (Galie=, 2008 - Ambrisentan vs Placebo

COMBI (Hoeper), 2006 - Inhaled iloprost vs Placebo

Singh, 2006 - Sildenafil vs Placebo

STEP (McLaughlin), 2006 - Inhaled iloprost vs Placebo

STRIDE-2 (Barst), 2006 - Sitaxsentan vs Placebo

BREATH-5 (Galie), 2006 - Bosentan vs Placebo

SERAPH (Wilkins), 2005 - Bosentan vs Sildenafil

SUPER-1 (Galie), 2005 - Sildenafil vs Placebo

STRIDE-1 (Barst), 2004 - Sitaxsentan vs Placebo

BREATH-2 (Humbert), 2004 - Epoprostenol + Bosentan vs Epoprostenol + placebo

Sastry, 2004 - Sildenafil vs Placebo

Barst, 2003 - Beraprost vs Placebo

BREATHE-1 (Rubin), 2002 - Bosentan vs Placebo

Langleben, 2002 - Terbogrel vs Placebo

AIR (Olschewski), 2002 - Iloprost vs Placebo

ALPHABET (Galie), 2002 - Beraprost vs Placebo

Simmoneau, 2002 - Treprostinil vs Placebo

Channick, 2001 - Bosentan vs Placebo

Badesch, 2000 - Epoprostenol vs control

Barst, 1996 - Epoprostenol vs control

Rubin, 1990 - Epoprostenol vs control



See also:

  • All pulmonary hypertension clinical trials
  • All clinical trials of All mecanism
  • All clinical trials of Bosentan
    		•  

    BREATHE-1 (Rubin) study, 2002

    Facebook    pdf : Bosentan - All mecanism for pulmonary hypertension

    Treatments

    Studied treatment Bosentan 125 or 250 mg twice daily (after 4 weeks of 62.5 mg of bosentan twice daily)
    Control treatment Placebo

    Patients

    Patients patients with pulmonary arterial hypertension (primary or associated with connective-tissue disease)

    Method and design

    Randomized effectives 144 / 69 (studied vs. control)
    Blinding double blind
    Follow-up duration 16 weeks
    Primary endpoint six-minute walk distance


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    Hospitalization for any reason

    6 / 144
         9 / 69
         0,32 [0,12;0,86]

    All cause death

    1 / 144
         2 / 69
         classic 0,24 [0,02;2,60]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    Hospitalization for any reason 6 / 144 (4,2%) 9 / 69 (13,0%) 0,32 [0,12;0,86]   10044 
    All cause death 1 / 144 (0,7%) 2 / 69 (2,9%) 0,24 [0,02;2,60]   10044 
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 10044: Gali� N, Manes A, Negro L, Palazzini M, Bacchi Reggiani ML, Branzi AEur Heart J 2009;:

    • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    Hospitalization for any reason 4,17% 13,04% -88,8‰
    All cause death 6,94‰ 2,90% -22,0‰

    Meta-analysis of all similar trials:

    All mecanism in pulmonary hypertension for all patients



    Reference(s)

    Trials register # NA
    • Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G. . N Engl J Med 2002;346:896-903 - 10.1056/NEJMoa012212
      Pubmed | Hubmed | Fulltext

    (c) 2004-2011 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend